The cell fate-determining roles played by members of the cyclin-dependent protein kinase (CDK) family explain why their dysregulation can promote proliferative diseases, and identify them as potential targets for drug discovery in oncology and beyond. After many years of research, the first efficacious CDK inhibitors have now been registered for clinical use in a defined segment of breast cancer. Research is underway to identify inhibitors with appropriate CDK-inhibitory profiles to recapitulate this success in other disease settings. Here, we review the structural data that illustrate the interactions and properties that confer upon inhibitors affinity and/or selectivity toward different CDK family members. We conclude that where CDK inhibitors display selectivity, that selectivity derives from exploiting active site sequence peculiarities and/or from the capacity of the target CDK(s) to access conformations compatible with optimizing inhibitor–target interactions.
Structure-based discovery of cyclin-dependent protein kinase inhibitors
- Views Icon Views
- Share Icon Share
Rob L.M. van Montfort, Paul Workman, Mathew P. Martin, Jane A. Endicott, Martin E.M. Noble; Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays Biochem 8 November 2017; 61 (5): 439–452. doi: https://doi.org/10.1042/EBC20170040
Download citation file: